When we discuss the trajectory of the synthetic biology (SynBio) industry, we aren’t just observing life; we are engineering it. But as any PI or Lab Manager knows, the “engineering” part of that equation depends entirely on the precision and reliability of your synthetic biology equipment.
The $70 Billion Inflection Point
In 2023, the market was just beginning to find its post-pandemic footing. The synthetic biology sector is no longer in its “experimental” phase. According to Grand View Research, the global market size reached $18.94 billion in 2025 and is on a trajectory toward $69.18 billion by 2033.
This 17.7% CAGR is being fueled by a surge in demand for specialized hardware. To keep pace, startups are moving beyond basic setups to integrated, high-throughput synthetic biology equipment workflows—from automated liquid handling to high-resolution mass spectrometry.
High-Output Science Requires High-End Hardware
In a SynBio lab, your instruments are your production line. We know that the leap from Seed to Series A often hinges on the quality of your data, which is why we specialize in financing the specific synthetic biology equipment categories that drive clinical and industrial milestones:
- Analytical Instrumentation: High-performance LC/MS and GC/MS systems for metabolic profiling and verifying engineered pathways.
- Gene Synthesis & Editing Tools: High-throughput PCR platforms and NGS (Next-Generation Sequencing) systems that allow for rapid “Design-Build-Test” cycles.
- Lab Automation: Robotic liquid handlers and biofoundry modules that reduce human error and increase reproducibility.
- Bioprocessing & Scale-up: Bioreactors and fermenters essential for moving from benchtop proof-of-concept to pilot-scale production.
The Capital Trap: Ownership vs. Access
The paradox of the SynBio revolution is that while the cost of DNA synthesis is dropping, the price tag on the necessary synthetic biology equipment remains a significant barrier to entry.
For a venture-backed startup, “owning” a depreciating asset like a $300k mass spec isn’t always the smartest move for the spreadsheet. It drains cash, shortens the runway, and creates “locked” capital.
Bold View Capital offers a different path. We provide flexible leasing and rental options for synthetic biology equipment that allow you to:
- Preserve Capital: Keep your VC dollars for talent and R&D.
- Stay Current: Avoid being stuck with legacy hardware when a more efficient model hits the market.
- Scale on Your Terms: Use our early buyout structures or rent-to-own models that flex with your grant timelines and fundraising cycles.
Early-stage businesses can finance equipment without diluting equity and protect their ownership stake in the business. Bold View Capital offers debt financing programs can help your business budget and plan for the future.
- $1 Buyout Capital Lease: Preserve your capital while acquiring lab equipment. At the end of the lease term, you own the equipment for a nominal fee – usually $1.
- 0% Over 12-Months Financing: Get the instrumentation you need without the high upfront cost. Spread the cost evenly over 12 payments without interest.
- Rentals-with-Equity: A rental-with-equity program is like a “try before you buy” plan. A set portion of your monthly rental payments goes towards buying the rented instrument at the end of the term.
The Only Leasing Partner Who Knows Your GC from Your GC/MS
We aren’t a bank that sees a “black box” on a balance sheet. We are science-native operators who understand the technical specifications of your synthetic biology equipment. We underwrite the risk differently because we understand the residual value of the instruments and the potential of the science they enable.
Every GC/MS, every fermentation system, and every analyzer is part of a larger system designed to move your company forward. That system deserves partners who understand its function, not just its cost.
Working with a financing partner who knows the science:
- Reduces back-and-forth during equipment setup
- Improves communication with vendors and installers
- Minimizes surprises during funding audits or investor check-ins
- Helps keep your team focused on data, not logistics
Preserve Capital. Scale Science.
The synthetic biology market is expected to nearly quadruple by 2033. To capture that growth, you need a lab outfitted with the best tools available today—without the “dilution tax” of traditional funding.
Is your lab infrastructure ready for the next milestone?
Contact Bold View Capital today to explore our synthetic biology equipment financing programs.
